ALISO VIEJO, Calif.,
May 30, 2014 /PRNewswire/
-- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today
announced that data related to the prevalence and treatment of
pseudobulbar affect (PBA), a distressing neurological condition
characterized by uncontrollable laughing or crying, will be
presented at the following conferences in June.
Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul
- Burden of pseudobulbar affect (PBA) symptoms in veterans with
traumatic brain injury (TBI)
- Abstract Number: A-635-0018-01071
- Poster Session: Neuro-epidemiology; Neurorehabilitation
- Time: June 1 at 12:30 p.m. EEST
- Dextromethorphan/Quinidine (DMQ) treatment significantly
increased percentage of days free of pseudobulbar affect (PBA)
episodes in a phase 3, randomized, placebo-controlled trial
- Abstract Number: A-635-0005-02074
- Poster Session: Clinical neurophysiology
- Time: June 1 at 12:30 p.m. EEST
- Dextromethorphan/Quinidine for treatment of pseudobulbar
affect: analysis of treatment-related adverse events
- Abstract Number: A-635-0005-02075
- Poster Session: Clinical neurophysiology
- Time: June 1 at 12:30 p.m. EEST
- Time to sustained remission of pseudobulbar affect (PBA)
episodes after treatment with dextromethorphan and quinidine
- Abstract Number: A-635-0005-02618
- Poster Session: Clinical neurophysiology
- Time: June 1 at 12:30 p.m. EEST
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR), May 31 - June, 4,
2014, Montreal
- Screening for PBA Symptoms Using a Single Question vs. a 7
Question Measure and Assessment of the Association of PBA Symptoms
with HRQOL Burden
- Abstract Number: PND45
- Session: Research Posters Session I
- Time: June 2 at 1:15 p.m. EDT
About PBA
PBA is a neurologic condition characterized
by uncontrollable, disruptive laughing and/or crying outbursts that
are often contrary or exaggerated to the patient's inner mood
state. As a result, many of those afflicted with PBA show
significant impairment on standard measures of health status, and
impairments in occupational and social function, often leading to
social isolation. PBA occurs secondary to a variety of neurologic
conditions such as traumatic brain injury (TBI), multiple sclerosis
(MS), amyotrophic lateral sclerosis (ALS), Parkinson's
disease, stroke and Alzheimer's disease. When these disorders
damage areas of the brain that regulate normal emotional
expression, they can lead to uncontrollable, disruptive episodes of
crying or laughing. For more information about PBA, please
visit www.pbafacts.com
About NUEDEXTA
NUEDEXTA is an innovative combination
of two well-characterized components; dextromethorphan hydrobromide
(20 mg), the ingredient active in the central nervous system, and
quinidine sulfate (10 mg), a metabolic inhibitor enabling
therapeutic dextromethorphan concentrations. NUEDEXTA acts on
sigma-1 and NMDA receptors in the brain, although the mechanism by
which NUEDEXTA exerts therapeutic effects in patients with PBA is
unknown.
NUEDEXTA Important Safety Information
NUEDEXTA is
indicated for the treatment of pseudobulbar affect (PBA). PBA
occurs secondary to a variety of otherwise unrelated neurological
conditions, and is characterized by involuntary, sudden, and
frequent episodes of laughing and/or crying. PBA episodes typically
occur out of proportion or incongruent to the underlying emotional
state.
Studies to support the effectiveness of NUEDEXTA were performed
in patients with amyotrophic lateral sclerosis (ALS) and multiple
sclerosis (MS). NUEDEXTA has not been shown to be safe and
effective in other types of emotional lability that can commonly
occur, for example, in Alzheimer's disease and other dementias.
NUEDEXTA and certain other medicines can interact, causing
serious side effects. If you take certain drugs or have certain
heart problems, NUEDEXTA may not be right for you.
NUEDEXTA causes dose-dependent QTc prolongation. When initiating
NUEDEXTA in patients at risk for QT prolongation and torsades de
pointes, electrocardiographic (ECG) evaluation should be conducted
at baseline and 3-4 hours after the first dose.
The most common adverse reactions are diarrhea, dizziness,
cough, vomiting, asthenia, peripheral edema, urinary tract
infection, influenza, increased gamma-glutamyltransferase, and
flatulence. NUEDEXTA may cause dizziness.
These are not all the risks from use of NUEDEXTA. Please refer
to full Prescribing Information at www.NUEDEXTA.com.
About Avanir Pharmaceuticals, Inc.
Avanir
Pharmaceuticals, Inc. is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous
system disorders of high unmet medical need. As part of our
commitment, we have extensively invested in our pipeline and are
dedicated to advancing medicines that can substantially improve the
lives of patients and their loved ones. For more information about
Avanir, please visit www.avanir.com.
AVANIR® is a trademark or registered trademark of Avanir
Pharmaceuticals, Inc. in the United
States and other countries.
©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700
Brewlife Media Contact
Nicole
Foderaro
nfoderaro@brewlife.com
+1 (415) 946-1058
Logo -
http://photos.prnewswire.com/prnh/20130207/LA55901LOGO
SOURCE Avanir Pharmaceuticals, Inc.